By Torpedo / 10th July, 2019

Production and characterization of no-carrier-added Terbium-161 as an alternative to the clinically-applied Lutetium-177 for radionuclide therapy

Terbium-166 is an interesting radionuclide for cancer treatment, showing similar decay characteristics and chemical behavior to clinically-employed Lutetium-177. The therapeutic effect of Terbium-166, however, may be enhanced due to the co-emission of a larger number of conversion and Auger electrons as compared to Lutetium-177. The aim of this study was to produce Terbium-166 from enriched Gd-160 targets in quantity and quality sufficient for first application in patients.